Soluble Frizzled-7 Receptor and Its Role in Liver Cancer Treatment
Author Information
Author(s): Wei Wei, Chua Mei-Sze, Grepper Susan, So Samuel K
Primary Institution: Stanford University School of Medicine
Hypothesis
The extracellular domain of FZD7 (sFZD7) would be a clinically more relevant therapeutic modality than previously studied approaches to target FZD7.
Conclusion
sFZD7 is a feasible therapeutic agent that can enhance the effects of doxorubicin in treating hepatocellular carcinoma.
Supporting Evidence
- sFZD7 decreased viability of three HCC cell lines but had little effect on normal hepatocytes.
- sFZD7 enhanced the growth inhibitory effects of doxorubicin against HCC cells in vitro.
- In vivo, sFZD7 combined with doxorubicin significantly delayed tumor growth in Huh7 xenografts.
Takeaway
Scientists found a new way to help treat liver cancer by using a special protein that makes cancer cells more sensitive to medicine.
Methodology
The study involved expressing and purifying sFZD7 from E. coli, testing its ability to inhibit Wnt3-mediated signaling, and evaluating its effects on HCC cell viability and doxorubicin sensitivity.
Participant Demographics
Three human hepatoma cell lines (HepG2, Hep40, and Huh7) and normal hepatocytes from three donors were used.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website